Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +54.31%
#2 Pons Pons +50.10%
#3 TENDIES TENDIES +37.91%
#4 StonkBroker StonkBroker +37.83%
#5 Magma Finance Magma Finance +37.19%
#6 PondCoin PondCoin +37.18%
#7 Ocean Protocol Ocean Protocol +33.58%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +27.14%
#9 Official Trump Official Trump +26.95%
#10 Starpower Starpower +26.92%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
Actuate Therapeutics Inc Actuate Therapeutics Inc

Actuate Therapeutics Inc

ACTU
Rank in Stocks #28698
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the... Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Share Price
$1.05
Market Cap
$25.12M
Change (1 day)
0.00%
Change (1 year)
-86.83%
Country
US
Trade Actuate Therapeutics Inc (ACTU)

Category

Healthcare
P/E ratio for Actuate Therapeutics Inc (ACTU)
P/E ratio as of 2026 TTM: 0
According to Actuate Therapeutics Inc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Actuate Therapeutics Inc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.